Horizant

Horizant is a brand name of gabapentin, approved by the FDA in the following formulation(s):

HORIZANT (gabapentin enacarbil - tablet, extended release; oral)

• 
  Manufacturer: GLAXO GRP LTD
  
  Approval date: April 6, 2011
  
  Strength(s): 600MG ^[RLD]


• 
  Manufacturer: GLAXO GRP LTD
  
  Approval date: December 13, 2011
  
  Strength(s): 300MG
  

Has a generic version of Horizant been approved?

No. There is currently no therapeutically equivalent version of Horizant available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Horizant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Prodrugs of GABA analogs, compositions and uses thereof
  Patent 6,818,787
  Issued: November 16, 2004
  Inventor(s): Mark A.; Gallop & Kenneth C.; Cundy & Cindy X.; Zhou & Fenmei; Yao & Jia-Ning; Xiang
  Assignee(s): Xenoport, Inc.
  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
  
  Patent expiration dates:
  
  
  • November 6, 2022
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Crystalline form of γ-aminobutyric acid analog
  Patent 8,026,279
  Issued: September 27, 2011
  Inventor(s): Estrada; Tono & Raillard; Stephen P.
  Assignee(s): XenoPort, Inc.
  A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided.
  
  Patent expiration dates:
  
  
  • November 10, 2026
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Prodrugs of GABA analogs, compositions and uses thereof
  Patent 8,048,917
  Issued: November 1, 2011
  Inventor(s): Gallop; Mark A. & Cundy; Kenneth C. & Zhou; Cindy X. & Yao; Fenmei & Xiang; Jia-Ning
  Assignee(s): XenoPort, Inc.
  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
  
  Patent expiration dates:
  
  
  • November 6, 2022
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 6, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Horizant Consumer Information (Drugs.com)
• Horizant Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Horizant Consumer Information (Cerner Multum)
• Gabapentin Consumer Information (Drugs.com)
• Gabapentin Consumer Information (Wolters Kluwer)
• Gabapentin Capsules Consumer Information (Wolters Kluwer)
• Gabapentin Enacarbil Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Gabapentin Solution Consumer Information (Wolters Kluwer)
• Gabapentin Consumer Information (Cerner Multum)
• FusePaq Fanatrex Advanced Consumer Information (Micromedex)
• Gabapentin Advanced Consumer Information (Micromedex)
• Gabapentin AHFS DI Monographs (ASHP)